Gradient Investments’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-619
| Closed | -$42.5K | – | 706 |
|
|
2024
Q2 | $42.5K | Buy |
619
+354
| +134% | +$23.6K | ﹤0.01% | 517 |
|
|
2024
Q1 | $19.4K | Sell |
265
-247
| -48% | -$19K | ﹤0.01% | 550 |
|
|
2023
Q4 | $41.5K | Buy |
512
+6
| +1% | +$467 | ﹤0.01% | 582 |
|
|
2023
Q3 | $37.9K | Sell |
506
-6
| -1% | -$461 | ﹤0.01% | 561 |
|
|
2023
Q2 | $39.5K | Sell |
512
-133
| -21% | -$10.6K | ﹤0.01% | 550 |
|
|
2023
Q1 | $53.5K | Sell |
645
-115
| -15% | -$9.53K | ﹤0.01% | 486 |
|
|
2022
Q4 | $65.2K | Sell |
760
-98
| -11% | -$7.76K | ﹤0.01% | 448 |
|
|
2022
Q3 | $53K | Sell |
858
-194
| -18% | -$12.2K | ﹤0.01% | 473 |
|
|
2022
Q2 | $65K | Buy |
1,052
+203
| +24% | +$12.6K | ﹤0.01% | 433 |
|
|
2022
Q1 | $50K | Sell |
849
-67
| -7% | -$4.28K | ﹤0.01% | 475 |
|
|
2021
Q4 | $67K | Buy |
916
+138
| +18% | +$9.51K | ﹤0.01% | 427 |
|
|
2021
Q3 | $54K | Sell |
778
-82
| -10% | -$5.76K | ﹤0.01% | 470 |
|
|
2021
Q2 | $59K | Sell |
860
-6
| -0.7% | -$401 | ﹤0.01% | 450 |
|
|
2021
Q1 | $56K | Buy |
866
+518
| +149% | +$33.4K | ﹤0.01% | 449 |
|
|
2020
Q4 | $22K | Hold |
348
| – | – | ﹤0.01% | 549 |
|
|
2020
Q3 | $22K | Sell |
348
-502
| -59% | -$34.8K | ﹤0.01% | 552 |
|
|
2020
Q2 | $65K | Buy |
850
+633
| +292% | +$48.5K | ﹤0.01% | 350 |
|
|
2020
Q1 | $16K | Sell |
217
-25,443
| -99% | -$1.76M | ﹤0.01% | 559 |
|
|
2019
Q4 | $1.67M | Buy |
25,660
+3,174
| +14% | +$207K | 0.07% | 144 |
|
|
2019
Q3 | $1.43M | Buy |
22,486
+5,102
| +29% | +$334K | 0.07% | 171 |
|
|
2019
Q2 | $1.17M | Buy |
17,384
+13,504
| +348% | +$888K | 0.06% | 174 |
|
|
2019
Q1 | $252K | Buy |
3,880
+2,804
| +261% | +$186K | 0.02% | 234 |
|
|
2018
Q4 | $67K | Buy |
1,076
+149
| +16% | +$10.4K | ﹤0.01% | 311 |
|
|
2018
Q3 | $72K | Buy |
927
+400
| +76% | +$30.2K | ﹤0.01% | 324 |
|
|
2018
Q2 | $37K | Sell |
527
-18
| -3% | -$1.27K | ﹤0.01% | 379 |
|
|
2018
Q1 | $41K | Buy |
545
+44
| +9% | +$3.5K | ﹤0.01% | 373 |
|
|
2017
Q4 | $36K | Buy |
+501
| New | +$38K | ﹤0.01% | 392 |
|
|
2017
Q3 | – | Sell |
-401
| Closed | -$28K | – | 416 |
|
|
2017
Q2 | $28K | Sell |
401
-100
| -20% | -$6.65K | ﹤0.01% | 366 |
|
|
2017
Q1 | $34K | Buy |
501
+112
| +29% | +$7.88K | ﹤0.01% | 346 |
|
|
2016
Q4 | $28K | Sell |
389
-63,151
| -99% | -$4.69M | ﹤0.01% | 323 |
|
|
2016
Q3 | $5.03M | Buy |
63,540
+60,264
| +1,840% | +$4.9M | 0.49% | 43 |
|
|
2016
Q2 | $273K | Sell |
3,276
-120
| -4% | -$10.7K | 0.03% | 167 |
|
|
2016
Q1 | $312K | Sell |
3,396
-68
| -2% | -$6.13K | 0.04% | 142 |
|
|
2015
Q4 | $351K | Sell |
3,464
-163
| -4% | -$17K | 0.05% | 151 |
|
|
2015
Q3 | $356K | Buy |
3,627
+3,607
| +18,035% | +$401K | 0.05% | 133 |
|
|
2015
Q2 | $2K | Sell |
20
-656
| -97% | -$71.7K | ﹤0.01% | 523 |
|
|
2015
Q1 | $66K | Buy |
676
+651
| +2,604% | +$66.1K | 0.01% | 218 |
|
|
2014
Q4 | $2K | Buy |
+25
| New | +$2.59K | ﹤0.01% | 486 |
|
|
2014
Q1 | – | Sell |
-43
| Closed | -$3K | – | 566 |
|
|
2013
Q4 | $3K | Hold |
43
| – | – | ﹤0.01% | 471 |
|
|
2013
Q3 | $3K | Hold |
43
| – | – | ﹤0.01% | 378 |
|
|
2013
Q2 | $2K | Buy |
+43
| New | +$2.24K | ﹤0.01% | 364 |
|
Other funds holding GILD
Gradient Investments's GILD Position: Q3 2024 in Review
Gradient Investments sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 619 shares — an estimated $42.5K sold.
Gradient Investments first reported a position in GILD in Q2 2013 and held it in 41 quarters. The position peaked at $5.03M in Q3 2016. 1,718 funds tracked by Wall St. Rank hold GILD as of Q3 2024.
- Gradient Investments reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
- Gradient Investments sold 619 Gilead Sciences shares in Q3 2024, an estimated $42.5K.
- Gradient Investments first reported a position in Gilead Sciences in Q2 2013 and held it in 41 quarters.
- Gradient Investments's Gilead Sciences position peaked at $5.03M in Q3 2016.
- 1,718 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.
Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.